Free tool
FAERS Monitor: Gallium Ga 68 Edotreotide
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210828 or its brand name (Gallium Ga 68 Edotreotide, Gallium Ga-68 Edotreotide). Reports on generic versions are filed under their own applications.
Reports
7
Serious
2
29% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- potentiating drug interaction5
- extravasation1
- hypokalaemia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2025 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,152 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| potentiating drug interactionSignal | 5 | 4483.8 | 2803.1 | 18,126 |
| extravasation | 1 | 731.3 | 119.1 | 182 |
| hypokalaemia | 1 | 65.1 | 10.6 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.